Comparison of Serum Procalcitonin Levels between Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) and Patients with Chronic Obstructive Pulmonary Disease

IF 0.2 Q4 RESPIRATORY SYSTEM

Current Respiratory Medicine Reviews Pub Date : 2023-03-15 DOI:10.2174/1573398x19666230315124509

Mohsen Shafiepour, Sakineh Haj Jafari Nejad, A. Behzadi, Behnam Dalfardi, Ahmad Alinaghi Langari, H. Ahmadipour, A. Shafahi, M. S. Fekri

{"title":"Comparison of Serum Procalcitonin Levels between Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) and Patients with Chronic Obstructive Pulmonary Disease","authors":"Mohsen Shafiepour, Sakineh Haj Jafari Nejad, A. Behzadi, Behnam Dalfardi, Ahmad Alinaghi Langari, H. Ahmadipour, A. Shafahi, M. S. Fekri","doi":"10.2174/1573398x19666230315124509","DOIUrl":null,"url":null,"abstract":"\n\nThis study aimed to compare the serum levels of procalcitonin in the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and the patients with chronic obstructive pulmonary disease (COPD) in the emergency ward of Afzalipour Hospital in Kerman.\n\n\n\nThis study aimed to compare the serum levels of procalcitonin in the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and the patients with chronic obstructive pulmonary disease (COPD) in the emergency ward of Afzalipour Hospital in Kerman.\n\n\n\nThis cross-sectional study was conducted on 45 patients with stable COPD and 45 patients with AECOPD. Patients were divided into four groups based on COPD severity assessment. Serum procalcitonin levels were measured using an ELISA kit.\n\n\n\nThe mean age of patients in the exacerbation and the stable group was 60.97±12.61 and 62.53±11.04 years, respectively. Serum procalcitonin levels in two exacerbation groups (215.22±19.84) were higher than stable groups (127.92±8.97) (P=0.001). The accuracy of this test for diagnosing acute attack in terms of AECOPD was 77%, and the serum procalcitonin level of 132.6 was found to be the best cut-off point to diagnose acute disease. The mean serum procalcitonin levels of stage D patients in the acute attack group were substantially higher than those of stages D and B patients in the stable group (P = 0.001). Serum procalcitonin levels were related to body mass index (P=0.01), post-bronchodilator FEV1/FVC (P=0.028), and the number of hospitalizations per year (P=0.001). By increasing the serum procalcitonin levels, BMI and number of admissions per year increase, and post-bronchodilator FEV1/FVC decreases.\n\n\n\nThis cross-sectional study was conducted on 45 patients with stable COPD and 45 patients with AECOPD. Patients were divided into four groups based on COPD severity assessment. Serum procalcitonin levels were measured using an ELISA kit.\n\n\n\nThe mean serum levels of procalcitonin in the group with attacks due to COPD was significantly higher than the stable group.\n\n\n\nThe mean age of patients in the exacerbation and the stable group was 60.97±12.61 and 62.53±11.04 years, respectively. Serum procalcitonin levels in two exacerbation groups (215.22±19.84) were higher than stable groups (127.92±8.97) (P=0.001). The accuracy of this test for diagnosing acute attack in terms of AECOPD was 77%, and the serum procalcitonin level of 132.6 was found to be the best cut-off point to diagnose acute disease. The mean serum procalcitonin levels of stage D patients in the acute attack group were substantially higher than those of stages D and B patients in the stable group (P = 0.001).Serum procalcitonin levels were related to body mass index (P=0.01), post-bronchodilator FEV1/FVC (P=0.028), and the number of hospitalizations per year (P=0.001). By increasing the serum procalcitonin levels, BMI and number of admissions per year increase, and post-bronchodilator FEV1/FVC decreases.\n\n\n\nThe mean serum levels of procalcitonin in the group with attacks due to COPD was significantly higher than the stable group.\n\n\n\n-\n","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Respiratory Medicine Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573398x19666230315124509","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

This study aimed to compare the serum levels of procalcitonin in the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and the patients with chronic obstructive pulmonary disease (COPD) in the emergency ward of Afzalipour Hospital in Kerman. This study aimed to compare the serum levels of procalcitonin in the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and the patients with chronic obstructive pulmonary disease (COPD) in the emergency ward of Afzalipour Hospital in Kerman. This cross-sectional study was conducted on 45 patients with stable COPD and 45 patients with AECOPD. Patients were divided into four groups based on COPD severity assessment. Serum procalcitonin levels were measured using an ELISA kit. The mean age of patients in the exacerbation and the stable group was 60.97±12.61 and 62.53±11.04 years, respectively. Serum procalcitonin levels in two exacerbation groups (215.22±19.84) were higher than stable groups (127.92±8.97) (P=0.001). The accuracy of this test for diagnosing acute attack in terms of AECOPD was 77%, and the serum procalcitonin level of 132.6 was found to be the best cut-off point to diagnose acute disease. The mean serum procalcitonin levels of stage D patients in the acute attack group were substantially higher than those of stages D and B patients in the stable group (P = 0.001). Serum procalcitonin levels were related to body mass index (P=0.01), post-bronchodilator FEV1/FVC (P=0.028), and the number of hospitalizations per year (P=0.001). By increasing the serum procalcitonin levels, BMI and number of admissions per year increase, and post-bronchodilator FEV1/FVC decreases. This cross-sectional study was conducted on 45 patients with stable COPD and 45 patients with AECOPD. Patients were divided into four groups based on COPD severity assessment. Serum procalcitonin levels were measured using an ELISA kit. The mean serum levels of procalcitonin in the group with attacks due to COPD was significantly higher than the stable group. The mean age of patients in the exacerbation and the stable group was 60.97±12.61 and 62.53±11.04 years, respectively. Serum procalcitonin levels in two exacerbation groups (215.22±19.84) were higher than stable groups (127.92±8.97) (P=0.001). The accuracy of this test for diagnosing acute attack in terms of AECOPD was 77%, and the serum procalcitonin level of 132.6 was found to be the best cut-off point to diagnose acute disease. The mean serum procalcitonin levels of stage D patients in the acute attack group were substantially higher than those of stages D and B patients in the stable group (P = 0.001).Serum procalcitonin levels were related to body mass index (P=0.01), post-bronchodilator FEV1/FVC (P=0.028), and the number of hospitalizations per year (P=0.001). By increasing the serum procalcitonin levels, BMI and number of admissions per year increase, and post-bronchodilator FEV1/FVC decreases. The mean serum levels of procalcitonin in the group with attacks due to COPD was significantly higher than the stable group. -

查看原文本刊更多论文

慢性阻塞性肺疾病急性加重期(AECOPD)与慢性阻塞性肺疾病患者血清降钙素原水平的比较

本研究旨在比较克尔曼阿夫扎利普尔医院急诊病房的慢性阻塞性肺病急性加重期（AECOPD）患者和慢性阻塞性肺疾病（COPD）患者的血清降钙素原水平本研究对45例稳定期COPD患者和45例AECOPD患者进行了横断面研究。根据COPD严重程度评估，将患者分为四组。使用ELISA试剂盒测量血清降钙素原水平。病情恶化组和稳定组患者的平均年龄分别为60.97±12.61和62.53±11.04岁。两个急性加重组的血清降钙素原水平（215.22±19.84）高于稳定组（127.92±8.97）（P=0.001）。该试验对AECOPD急性发作的诊断准确率为77%，血清降钙素原水平132.6是诊断急性疾病的最佳分界点。急性发作组D期患者的平均血清降钙素原水平显著高于稳定组的D期和B期患者（P=0.001）。血清降钙素原水平与体重指数（P=0.01）、支气管扩张剂后FEV1/FVC（P=0.028）和每年住院人数（P=0.001）有关，BMI和每年入院人数增加，支气管扩张后FEV1/FVC降低。这项横断面研究对45名稳定期COPD患者和45名AECOPD患者进行。根据COPD严重程度评估，将患者分为四组。使用ELISA试剂盒测量血清降钙素原水平。COPD发作组的平均血清降钙素原水平显著高于稳定组。病情恶化组和稳定组患者的平均年龄分别为60.97±12.61和62.53±11.04岁。两个急性加重组的血清降钙素原水平（215.22±19.84）高于稳定组（127.92±8.97）（P=0.001）。该试验对AECOPD急性发作的诊断准确率为77%，血清降钙素原水平132.6是诊断急性疾病的最佳分界点。急性发作组D期患者的平均血清降钙素原水平显著高于稳定组的D期和B期患者（P=0.001）。血清降钙素原水平与体重指数（P=0.01）、支气管扩张剂后FEV1/FVC（P=0.028）和每年住院人数（P=0.001）有关，BMI和每年入院人数增加，支气管扩张后FEV1/FVC降低。COPD发作组的平均血清降钙素原水平显著高于稳定组-

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Respiratory Medicine Reviews RESPIRATORY SYSTEM-

CiteScore

0.60

自引率

0.00%

发文量

期刊介绍： Current Respiratory Medicine Reviews publishes frontier reviews on all the latest advances on respiratory diseases and its related areas e.g. pharmacology, pathogenesis, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in respiratory medicine.